Analyst Price Target is $24.77
▲ +19.25% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $24.77, with a high forecast of $32.00 and a low forecast of $5.00. The average price target represents a 19.25% upside from the last price of $20.77.
Current Consensus is
The current consensus among 11 contributing investment analysts is to buy stock in Immunovant. This rating has held steady since October 2021, when it changed from a Hold consensus rating.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.